Alyce Adams
Internal Medicine · West Monroe, LANPI 1700806767
Payments from drug & device makers
Across 173 payments — averaging $55.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Dexcom, Inc.$6K
- Lilly USA, LLC$584
- Bayer$477
- Novo Nordisk$473
- AstraZeneca$302
- Insulet Corporation$295
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$4,33645%
- Travel & lodging$1,52616%
- Food & beverage$3,67238%
- Education$450%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Dexcom, Inc. | 6 | $5,947 |
| Lilly USA, LLC | 28 | $584 |
| Bayer | 23 | $477 |
| Novo Nordisk | 30 | $473 |
| AstraZeneca | 12 | $302 |
| Insulet Corporation | 7 | $295 |
| Boehringer Ingelheim | 12 | $218 |
| Pfizer | 12 | $213 |
| Sanofi | 8 | $177 |
| Esperion Therapeutics, Inc. | 2 | $138 |
| Idorsia Pharmaceuticals US Inc | 1 | $117 |
| AbbVie | 4 | $89 |
| Abbott | 5 | $84 |
| GSK | 2 | $58 |
| Xeris Pharmaceuticals, Inc. | 3 | $50 |
| Sumitomo Pharma America, Inc. | 2 | $50 |
| Merck | 3 | $44 |
| Inspire Medical Systems, Inc. | 1 | $36 |
| Neurelis, Inc. | 1 | $33 |
| Amgen | 2 | $30 |
| Dynavax Technologies Corporation | 1 | $25 |
| Phathom Pharmaceuticals, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $21 |
| Lexicon Pharmaceuticals, Inc. | 1 | $20 |
| Ironwood Pharmaceuticals, Inc | 1 | $18 |
| Sanofi-aventis U.S. LLC | 1 | $15 |
| Avanir Pharmaceuticals, Inc. | 1 | $15 |
| Lundbeck LLC | 1 | $14 |
| Amarin Pharma, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DEXCOM G7 GSS (161)$5,841
- NEXLIZET$125
- NEXLETOL$125
- Omnipod$119
- QUVIVIQ$117
How this compares
$9,578 in reported general payments places this provider in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 114 | $147,767 |
| MounjaroTirzepatide | 108 | $136,593 |
| TrulicityDulaglutide | 66 | $91,645 |
| OzempicSemaglutide | 78 | $88,676 |
| EliquisApixaban | 66 | $62,254 |
| LinzessLinaclotide | 78 | $59,740 |
| RybelsusSemaglutide | 29 | $50,675 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 50 | $46,850 |
| KerendiaFinerenone | 50 | $41,658 |
| FarxigaDapagliflozin Propanediol | 38 | $41,000 |
| EntrestoSacubitril/Valsartan | 14 | $16,295 |
| XareltoRivaroxaban | 12 | $13,321 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 18 | $13,235 |
| TradjentaLinagliptin | 11 | $12,038 |
| JanumetSitagliptin Phos/Metformin Hcl | 12 | $11,107 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $584 | $231,064186 claims |
| Boehringer IngelheimJardiance, Tradjenta | $218 | $159,805125 claims |
| Novo NordiskOzempic, Rybelsus, Novolog | $473 | $143,043136 claims |
| PfizerEliquis | $213 | $62,25466 claims |
| AbbVieLinzess | $89 | $59,74078 claims |
| BayerKerendia | $477 | $41,65850 claims |
| AstraZenecaFarxiga | $302 | $41,00038 claims |
| MerckJanumet | $44 | $11,10712 claims |
| GSKTrelegy Ellipta | $58 | $10,34014 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,528 internal medicine providers in Louisiana.
Other internal medicine in West Monroe
- William SmithNew Orleans$50.5M
- Robert JeanfreauMetairie$13.4M
- Katherine PearceBaton Rouge$12M
- Ernest ThompsonBaker$2.1M
- Brian LewisNew Orleans$2M
- Otis BarnumNatchitoches$1.8M
- Satinder SainiCrowley$1.8M
- Randall MillerEunice$1.2M
- Donna RyanBaton Rouge$991K
- Steven DeitelzweigNew Orleans$939K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.